Servier BioInnovation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$166.9M
Doctors Paid
71
Transactions
6,787
2024 Total
$82.2M
Payment Breakdown by Category
Research$166.4M (99.7%)
Consulting$475,974 (0.3%)
Food & Beverage$1,876 (0.0%)
Travel$642.11 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $166.4M | 6,726 | 99.7% |
| Consulting Fee | $475,974 | 45 | 0.3% |
| Food and Beverage | $1,876 | 13 | 0.0% |
| Travel and Lodging | $642.11 | 2 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $340.00 | 1 | 0.0% |
Payments by Type
Research
$166.4M
6,726 transactions
General
$478,832
61 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | $34.2M | 7 | 953 |
| Phase Ib/II Investigator Sponsored Study of the IDH1-mutant inhibitor ivosidenib (AG120) with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies | $31.7M | 0 | 33 |
| STUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, INDIGO | $23.9M | 7 | 1,527 |
| Phase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab | $13.7M | 12 | 768 |
| SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | $9.4M | 0 | 432 |
| A PHASE I, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION, SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ACTIVITY STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH AN IDH1 MUTATION | $8.6M | 12 | 222 |
| TREATMENT OF NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS | $8.1M | 0 | 1 |
| A Phase II clinical trial of Ivosidenib for patients with clonal hematopoiesis mutations in IDH1a | $7.4M | 0 | 15 |
| STUDY OF ORALLY ADMINISTERED AG-120 IN SUBJECTS WITH ADVANCED SOLID TUMORS, INCLUDING GLIOMA, WITH AN IDH1 MUTATION | $6.1M | 0 | 109 |
| CALASPARGASE PEGOL IN ADULTS WITH ALL | $5.8M | 2 | 436 |
| PHASE III STUDY OF TRIFLURIDINE/TIPIRACIL IN COMBINATION WITH BEVACIZUMAB VS TRIFLURIDINE/TIPIRACIL SINGLE AGENT IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (SUNLIGHT) | $2.8M | 0 | 73 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation | $1.7M | 0 | 945 |
| S95029 Alone and in Combination with Sym021 in Patients with Advanced Solid Tumors followed by an Expansion Phase of Triple Combinations | $1.6M | 4 | 519 |
| A single Arm Phase 1b study of hyper-CVAD plus Asparlas in youngadults (18-50) with newly diagnosed ALL | $1.3M | 0 | 18 |
| A PHASE II STUDY OF AG-120 IN PATIENTS WITH RECURRENT OR LOCALLY ADVANCED/METASTATIC, IDH1 MUTANT, CHONDROSARCOMA | $1.2M | 0 | 3 |
| Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma | $1.2M | 0 | 115 |
| STUDY OF AG-270 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA WITH MTAP LOSS | $865,799 | 0 | 41 |
| Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) | $682,034 | 0 | 9 |
| A single Arm Phase 1b study of hyper CVAD plus Asparlas in young adults 18 to 50 with newly diagnosed ALL | $515,682 | 0 | 2 |
| Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | $480,261 | 0 | 151 |
| Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy) | $438,556 | 0 | 2 |
| A PHASE I, MULTICENTER, OPEN LABEL, DOSE DE-ESCALATION AND EXPANSION STUDY OF GEMCITABINE AND CISPLATIN | $427,306 | 0 | 2 |
| A Phase 1 Trial of Calaspargase Pegol-mknl in Combination with High Dose Cytarabine and Idarubicin in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia | $367,380 | 0 | 2 |
| A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl In Combination with Cobimetinib in Metastatic Pancreatic Cancer | $357,057 | 0 | 3 |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | $327,795 | 0 | 4 |
| Preventing ASNase-associated pancreatitis using the novel dimension of metabolomics and proteomics | $326,600 | 0 | 2 |
| PHASE I/II STUDY OF IDH1 INHIBITOR AG-120 AND NIVOLUMAB IN IDH1 MUTANT ADVANCED SOLID TUMORS | $321,886 | 0 | 1 |
| A PHASE 1 STUDY OF IDH1 INHIBITION USING IVOSIDENIB AS MAINTENANCE THERAPY FOR IDH1-MUTANT MYELOID NEOPLASMS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION | $285,644 | 0 | 3 |
| ASPARLAS COMBINED WITH MCL1 INHIBITOR IN AML IN A MURINE MODEL (S64315) | $265,836 | 0 | 3 |
| Asparlas combined with BCL2 in in relapsed/refractory AML in a murine model (S65487) | $246,127 | 0 | 2 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Hematology & Oncology | $243,455 | 15 | $16,230 |
| Hospitalist | $184,245 | 1 | $184,245 |
| Internal Medicine | $146,789 | 17 | $8,635 |
| Medical Oncology | $62,087 | 10 | $6,209 |
| Neurology | $58,669 | 12 | $4,889 |
| Pediatric Hematology-Oncology | $48,312 | 5 | $9,662 |
| Rheumatology | $32,505 | 1 | $32,505 |
| Pediatrics | $22,936 | 2 | $11,468 |
| Gastroenterology | $10,400 | 1 | $10,400 |
| Hematology | $9,761 | 3 | $3,254 |
| Student in an Organized Health Care Education/Training Program | $8,573 | 2 | $4,286 |
| Radiation Oncology | $3,503 | 1 | $3,503 |
| Surgery | $839.45 | 1 | $839.45 |
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Andrew Lassman, Md, MD | Neurology | New York, NY | $4,900 | $0 |
| Isabel Arrillaga-Romany, Md, Phd, MD, PHD | Internal Medicine | Boston, MA | $4,873 | $0 |
| Jaffer Ajani, M.d, M.D | Medical Oncology | Houston, TX | $3,740 | $0 |
| Samuel Klempner, M.d, M.D | Internal Medicine | Los Angeles, CA | $3,740 | $0 |
| Dr. James Harding, Md, MD | Hematology & Oncology | New York, NY | $3,740 | $0 |
| Mr. Peter Enzinger, Dr, DR | Medical Oncology | Boston, MA | $3,740 | $0 |
| Joseph Franses, Md, MD | Hematology & Oncology | Chicago, IL | $3,740 | $0 |
| Guillermo Garcia-Manero, M.d, M.D | Medical Oncology | Houston, TX | $3,675 | $0 |
| Dr. Praneeth Baratam, Md, MD | Internal Medicine | Charleston, SC | $3,675 | $0 |
| Dr. Gabrielle Prince, Md, MD | Internal Medicine | Baltimore, MD | $3,675 | $0 |
| Dr. Joohee Sul, Md, MD | Neurology | Rochester, NY | $3,640 | $0 |
| Dr. Helen Shih, Md, MD | Radiation Oncology | Boston, MA | $3,503 | $0 |
| Howard Colman, M.d, M.D | Neurology | Salt Lake City, UT | $3,503 | $0 |
| Macarena De La Fuente, M.d, M.D | Neurology | Miami, FL | $3,138 | $0 |
| John De Groot, M.d, M.D | Neurology | Houston, TX | $2,941 | $0 |
| Dr. Vinay Puduvalli, M.d, M.D | Neurology | Houston, TX | $2,941 | $0 |
| Dr. Priya Kumthekar, Md, MD | Neurology | Chicago, IL | $2,941 | $0 |
| William Sellers, M.d, M.D | Internal Medicine | Cambridge, MA | $2,814 | $0 |
| Jonathan Trent, M.d., Ph. D, M.D., PH. D | Medical Oncology | Miami, FL | $2,800 | $0 |
| Mr. Alan Dandrea, Md, MD | Pediatric Hematology-Oncology | Boston, MA | $2,720 | $0 |
| Dr. Courtney Dinardo, Md, MD | Internal Medicine | Houston, TX | $2,257 | $0 |
| Dr. Jason Luke, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $2,170 | $0 |
| Dr. Elizabeth Maher, Md, Phd, MD, PHD | Hematology & Oncology | Dallas, TX | $1,932 | $0 |
| Dr. Eytan Stein, M.d, M.D | Internal Medicine | New York, NY | $1,683 | $0 |
| Dr. Richard Stone, Md, MD | Hematology & Oncology | Boston, MA | $1,683 | $0 |
Ad
Top Products
- Tibsovo $91.6M
- Voranigo $19.9M
Associated Products (10)
Payment Categories
- Food & Beverage $1,876
- Consulting $475,974
- Travel & Lodging $642.11
- Research $166.4M
About Servier BioInnovation
Servier BioInnovation has made $166.9M in payments to 71 healthcare providers, recorded across 6,787 transactions in the CMS Open Payments database. In 2024, the company paid $82.2M. The top product by payment volume is Tibsovo ($91.6M).
Payments were distributed across 13 medical specialties. The top specialty by payment amount is Hematology & Oncology ($243,455 to 15 doctors).
Payment categories include: Food & Beverage ($1,876), Consulting ($475,974), Research ($166.4M), Travel & Lodging ($642.11).
Servier BioInnovation is associated with 10 products in the CMS Open Payments database, including Tibsovo, Voranigo, and Asparlas.